左心房整体长轴应变参数在心脏毒性诊断中的评价

封面

如何引用文章

全文:

详细

一系列极其有效的化疗药物对心血管系统有负面影响，从而找平了癌症治疗的成功。因此，心脏毒性的早期诊断非常重要，可以及时采取预防和治疗措施。

使用超声心动图测定左心室射血分数是评估心脏功能的基本无创仪器方法，也是化疗期间诊断心功能不全的主要指南。然而，在亚临床病变中，该指数可能在很长一段时间内保持正常，并且还具有明显的操作者间变异性和对体积负荷的依赖性。专家们一直在寻找最佳的超声心动图参数，以便在早期阶段诊断出心功能失调。左心房整体长轴应变的分析似乎是对于这些目的的有前途的方法。大量积累的数据表明，左心房不仅仅是一个导管，而是反映了左心室的充盈压力，是其收缩和舒张功能障碍的敏感标志。

本综述分析了目前关于使用心脏毒性药物诊断心脏功能障碍的左心房整体长轴应变的现有研究。

作者简介

Anastasiya V. Yusupova

Clinical Hospital of St. Luke

编辑信件的主要联系方式.
Email: yusupova@lucaclinic.ru
ORCID iD: 0000-0002-0763-0537
SPIN 代码: 1492-1947
俄罗斯联邦, Saint-Petersburg

Einar S. Yusupov

North-Western District Scientific and Clinical Center named after L.G. Sokolov

Email: usupov_as@mail.ru
ORCID iD: 0000-0002-4716-0314
SPIN 代码: 6632-4484

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

参考

  1. Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287. doi: 10.1016/J.MAYOCP.2014.05.013
  2. Okwuosa TM, Anzevino S, Rao R. Cardiovascular disease in cancer survivors. Postgrad Med J. 2017;93(1096):82–90. doi: 10.1136/POSTGRADMEDJ-2016-134417
  3. Fidler MM, Reulen RC, Henson K, et al. Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in Great Britain. Circulation. 2017;135(10):951–963. doi: 10.1161/CIRCULATIONAHA.116.024811
  4. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and s urvivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi: 10.3322/CAAC.21565
  5. Valero-Elizondo J, Chouairi F, Khera R, et al. Atherosclerotic cardiovascular disease, cancer, and financial toxicity among adults in the United States. JACC CardioOncology. 2021;3(2):236–246. doi: 10.1016/J.JACCAO.2021.02.006
  6. Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. JJCO Japanese J Clin Oncol. 2017;47(8):678–682. doi: 10.1093/jjco/hyx068
  7. Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536–2551. doi: 10.1016/j.jacc.2017.09.1096
  8. Armstrong GT, Ross JD. Late cardiotoxicity in aging adult survivors of childhood cancer. Prog Pediatr Cardiol. 2014;36(1-2):19. doi: 10.1016/J.PPEDCARD.2014.09.003
  9. Lati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–1680. doi: 10.1093/eurheartj/ehw022
  10. Lopez-Mattei JC, Hassan S. The SUCCOUR trial: a cardiovascular imager’s perspective ― American College of Cardiology [Electronic resource]. Available from: https://www.acc.org/latest-in-cardiology/articles/2021/04/16/13/09/the-succour-trial. Accessed: 15.02.2022.
  11. Laufer-Perl M, Gilon D, Kapusta L, Iakobishvili Z. The role of speckle strain echocardiography in the diagnosis of early subclinical cardiac injury in cancer patients ― is there more than just left ventricle global longitudinal strain? J Clin Med. 2021;10(1):154. doi: 10.3390/JCM10010154
  12. Laufer-Pearl M, Arnold JH, Mor L, et al. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy. Clin Res Cardiol. 2020;109(2):255–262. doi: 10.1007/S00392-019-01508-9
  13. Choi JO, Shin DH, Cho SW, et al. Effect of preload on left ventricular longitudinal strain by 2D speckle tracking. Echocardiography. 2008;25(8):873–879. doi: 10.1111/j.1540-8175.2008.00707.x
  14. Santoro C, Arpino G, Esposito R, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017;18(8):930–936. doi: 10.1093/ehjci/jex033
  15. Santoro C, Esposito R, Lembo M, et al. Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 2019;20(12):1345–1352. doi: 10.1093/ehjci/jez194
  16. Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77(4):392–401. doi: 10.1016/j.jacc.2020.11.020
  17. Dobson R, Ghosh AK, Ky B, et al. BSE and BCOS guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. JACC CardioOncology. 2021;3(1):1–16. doi: 10.1016/J.JACCAO.2021.01.011
  18. Kuznetsova T, Thijs L, Knez J, et al. Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Hear Assoc Cardiovasc Cerebrovasc Dis. 2014;3(3):e000789. doi: 10.1161/JAHA.114.000789
  19. Nagiub M, Nixon JV, Kontos MC. Ability of nonstrain diastolic parameters to predict doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis. Cardiol Rev. 2018;26(1):29–34. doi: 10.1097/CRD.0000000000000161
  20. Upshaw JN, Finkelman B, Hubbard RA, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging. 2020;13(1):198–210. doi: 10.1016/J.JCMG.2019.07.018
  21. Mincu RI, Lampe LF, Mahabadi AA, et al. Left ventricular diastolic function following anthracycline-based chemotherapy in patients with breast cancer without previous cardiac disease ― a meta-analysis. J Clin Med. 2021;10(17):3890. doi: 10.3390/JCM10173890
  22. Rossi A, Temporelli PL, Quintana M, et al. Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE Heart Failure). Eur J Heart Fail. 2009;11(10):929–936. doi: 10.1093/EURJHF/HFP112
  23. Benjamin E, D’Agostino R, Belanger A. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92(4):835–841. doi: 10.1161/01.CIR.92.4.835
  24. Thomas L, Marwick HT, Popescu AB, et al. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC state of the art review. J Am Coll Cardiol. 2019;73(15):1961–1977. doi: 10.1016/J.JACC.2019.01.059
  25. Serezhina EK, Obrezan AG. Significance of the echocardiographic evaluation of left atrial myocardial strain for early diagnosis of heart failure with preserved ejection fraction. Kardiologiia. 2021;61(8):68–75. (In Russ). doi: 10.18087/cardio.2021.8.n1418
  26. Kebed KY, Addetia K, Lang RM. Importance of the left atrium: more than a bystander? Heart Fail Clin. 2019;15(2):191–204. doi: 10.1016/j.hfc.2018.12.001
  27. Litwin SE. Left atrial strain: a single parameter for assessing the dark side of the cardiac cycle? JACC Cardiovasc Imaging. 2020;13(10):2114–2116. doi: 10.1016/j.jcmg.2020.07.037
  28. Alekhin МN, Kalinin АО. Diastolic function of the left ventricle: the meaning of left atrium longitudinal strain. Ultrasound Funct Diagnostics. 2020;(3):91–104. (In Russ). doi: 10.24835/1607-0771-2020-3-91-104
  29. Szilveszter B, Nagy AI, Vattay B, et al. Left ventricular and atrial strain imaging with cardiac computed tomography: validation against echocardiography. J Cardiovasc Comput Tomogr. 2020;14(4):363–369. doi: 10.1016/j.jcct.2019.12.004
  30. Kim J, Yum B, Palumbo MC, et al. Left atrial strain impairment precedes geometric remodeling as a marker of post-myocardial infarction diastolic dysfunction. JACC Cardiovasc Imaging. 2020;13(10):2099–2113. doi: 10.1016/j.jcmg.2020.05.041
  31. Pathan F, Zainal Abidin HA, Vo QH, et al. Left atrial strain: a multi-modality, multi-vendor comparison study. Eur Heart J Cardiovasc Imaging. 2021;22(1):102–110. doi: 10.1093/ehjci/jez303
  32. Genovese D, Singh A, Volpato V, et al. Load dependency of left atrial strain in normal subjects. J Am Soc Echocardiogr. 2018;31(11):1221–1228. doi: 10.1016/j.echo.2018.07.016
  33. Brecht A, Oertelt-Prigione S, Seeland U, et al. Left Atrial function in preclinical diastolic dysfunction: two-dimensional speckle-tracking echocardiography ― derived results from the BEFRI trial. J Am Soc Echocardiogr. 2016;29(8):750–758. doi: 10.1016/j.echo.2016.03.013
  34. Lundberg A, Johnson J, Hage C, et al. Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study. Clin Res Cardiol. 2019;108:703–715. doi: 10.1007/s00392-018-1399-8
  35. Mandoli GE, Sisti N, Mondillo S, et al. Left atrial strain in left ventricular diastolic dysfunction: have we finally found the missing piece of the puzzle? Heart Fail Rev. 2020;25(3):409–417. doi: 10.1007/s10741-019-09889-9
  36. Pathan F, D’Elia N, Nolan MT, et al. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr. 2017;30(1):59–70.e8. doi: 10.1016/j.echo.2016.09.007
  37. Monte I, Bottari V, Buccheri S, et al. Chemotherapy-induced cardiotoxicity: subclinical cardiac dysfunction evidence using speckle tracking echocardiography. J Cardiovasc Echogr. 2013;23(1):33–38. doi: 10.4103/2211-4122.117983
  38. Sonaglioni A, Albini A, Fossile E, et al. Speckle-tracking echocardiography for cardioncological evaluation in bevacizumab-treated colorectal cancer patients. Cardiovasc Toxicol. 2020;20(6):581–592. doi: 10.1007/s12012-020-09583-5
  39. Meloche J, Nolan M, Amir E, et al. Temporal changes in left atrial function in women with HER2+ breast cancer receivig sequential anthracyclines and trastuzumab therapy. J Am Coll Cardiol. 2018;71(11):A1524. doi: 10.1016/s0735-1097(18)32065-5
  40. Emerson P, Stefani L, Terluk A, et al. Left atrial strain analysis in breast cancer patients post anthracycline (AC). Hear Lung Circ. 2021;30:S196. doi: 10.1016/j.hlc.2021.06.225
  41. Laufer-Perl M, Arias O, Dorfman SS, et al. Left atrial strain changes in patients with breast cancer during anthracycline therapy. Int J Cardiol. 2021;330:238–244. doi: 10.1016/J.IJCARD.2021.02.013
  42. Moustafa S, Murphy K, Nelluri BK, et al. Temporal trends of cardiac chambers function with trastuzumab in human epidermal growth factor receptor ii-positive breast cancer patients. Echocardiography. 2016;33(3):406–415. doi: 10.1111/echo.13087
  43. Moreno J, García-Sáez JA, Clavero M, et al. Effect of breast cancer cardiotoxic drugs on left atrial myocardium mechanics. Searching for an early cardiotoxicity marker. Int J Cardiol. 2016;210:32–34. doi: 10.1016/j.ijcard.2016.02.093
  44. Setti E, Dolci G, Bergamini C, et al. P2460 prospective evaluation of atrial function by 2D speckle tracking analysis in HER-2 positive breast cancer patients during Trastuzumab therapy. Eur Heart J. 2019;40(Suppl 1):2460. doi: 10.1093/eurheartj/ehz748.0792
  45. Moustafa S, Ho TH, Shah P, et al. Predictors of Incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors. J Clin Ultrasound. 2016;44(4):221. doi: 10.1002/JCU.22333
  46. Anqi Y, Yu Z, Mingjun X, et al. Use of echocardiography to monitor myocardial damage during anthracycline chemotherapy. Echocardiography. 2019;36(3):495–502. doi: 10.1111/echo.14252
  47. Timóteo AT, Moura Branco L, Filipe F, et al. Cardiotoxicity in breast cancer treatment: What about left ventricular diastolic function and left atrial function? Echocardiography. 2019;36(10):1806–1813. doi: 10.1111/echo.14487
  48. Park H, Kim KH, Kim HY, et al. Left atrial longitudinal strain as a predictor of cancer therapeutics-related cardiac dysfunction in patients with breast cancer. Cardiovasc Ultrasound. 2020;18(1):1–8. doi: 10.1186/S12947-020-00210-5
  49. Di Lisi D, Cadeddu Dessalvi C, Manno G, et al. Left atrial strain and left atrial stiffness for early detection of cardiotoxicity in cancer patients. Eur Heart J. 2021;42(Suppl 1):2021. doi: 10.1093/eurheartj/ehab724.021
  50. Li VW, Lai CT, Liu AP, et al. Left atrial mechanics and integrated calibrated backscatter in anthracycline-treated long-term survivors of childhood cancers. Ultrasound Med Biol. 2017;43(9):1897–1905. doi: 10.1016/j.ultrasmedbio.2017.05.017
  51. Loar RW, Colquitt JL, Rainusso NC, et al. Assessing the left atrium of childhood cancer survivors. Int J Cardiovasc Imaging. 2021;37(1):155–162. doi: 10.1007/s10554-020-01970-x
  52. Patel NR, Chyu CK, Satou GM, et al. Left atrial function in children and young adult cancer survivors treated with anthracyclines. Echocardiography. 2018;35(10):1649–1656. doi: 10.1111/echo.14100
  53. Tadic M, Genger M, Cuspidi C, et al. Phasic left atrial function in cancer patients before initiation of anti-cancer therapy. J Clin Med. 2019;8(4):421. doi: 10.3390/JCM8040421
  54. Liao JN, Chao TF, Kuo JY, et al. Age, sex, and blood pressure-related influences on reference values of left atrial deformation and mechanics from a large-scale asian population. Circ Cardiovasc Imaging. 2017;10(10):e006077. doi: 10.1161/CIRCIMAGING.116.006077
  55. Cameli M, Mandoli GE, Loiacono F, et al. Left atrial strain: a new parameter for assessment of left ventricular filling pressure. Heart Fail Rev. 2016;21(1):65–76. doi: 10.1007/S10741-015-9520-9
  56. Singh A, El Hangouche N, McGee K, et al. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib. Echocardiography. 2021;38(1):81–88. doi: 10.1111/echo.14946

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Yusupova A.V., Yusupov E.S., 2022

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。

##common.cookie##